Image For Activity Cover
GRACIOEM2303 - CME/CMLE - Advanced Melanoma: The Evolving Role of Biomarker Testing in Treatment and Prognosis
Course Description

Advanced Melanoma: The Evolving Role of Biomarker Testing in Treatment and Prognosis
 
This activity is designed to engage pathologists, laboratory professionals, and other members of the multidisciplinary cancer care team in improving the diagnosis, biomarker testing, and treatment of patients with advanced melanoma.
Course topics include:

  • Advanced melanoma
  • Biomarkers for diagnosis
  • Biomarkers of prognosis
  • Biomarkers of response to therapy

Faculty/Authors
Carlos Torres-Cabala, MD FASCP
Professor, Department of Pathology and Dermatology
Section Chief, Dermatology
Division of Pathology/Laboratory Medicine
The University of Texas MD Anderson Cancer Center, Houston, Texas 

Target Audience
This activity has been designed to meet the educational needs of pathologists and laboratory professionals.
 
Accreditation Statement
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

Physician's Competency: Patient Care, Medical Knowledge, Practice-Based Learning and Improvement

CME/CMLE Credit: 0.5
Estimated Completion Time: 0.5 hour
Format: Online educational activity

Credit Designation Statement
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
 
The ASCP designates this activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
 
ASCP designates this activity for a maximum of 0.5 CMLE credit.  This activity meets CMP and state re-licensure requirements for laboratory personnel.
 
For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, during normal business hours: Monday through Friday, 8 a.m. to 6 p.m. Eastern Time

Method of Participation
To complete the activity and receive credit, the participant must complete the online activity. CME certificates will be provided online.
 
Commercial Support
This activity is funded by an independent educational grant from Bristol Myers Squibb.

Instructions

To claim CME/CMLE credit for the exercise, do the following:

  1. Review the Technical Considerations.
  2. Click Go to Content and click the first module of the course.
  3. Complete the Demographic Survey.
  4. Complete the Pre-Test.
  5. Review the Educational Activity.
  6. Complete and submit the Post Exam. You will have a maximum of three attempts to obtain the required score. You will be notified if you have met the credit requirements after each attempt.
  7. Submit the course Evaluation.
  8. Enter the maximum number of credits offered and click Claim CME/CMLE to register credit.

Faculty Disclosures 

Technical Considerations 

Release Dates: 11/1/2023
Review Date:
Expiration Date: 11/1/2026 




Course Objectives

Upon completion of this activity, you will be able to:

  • Identify available biomarker tests for diagnosis, prognosis, and prediction of response to therapy in patients with melanoma  

  • Discuss evolving concepts in appropriate biomarker testing for patients with melanoma  

 
Summary
Availability: On-Demand
Credit Offered:
0.5 CME/CMLE Credit
Powered By